Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older
• People who have been diagnosed with an aggressive B-cell blood cancer (specifically a type called DLBCL or a transformed indolent B-cell lymphoma), confirmed by a tissue sample
• People whose cancer has come back or stopped responding to treatment, and who have already received at least 2 previous treatments — and who have either never had a specific type of antibody therapy targeting CD3 and CD20 (Group 1), or have run out of all standard available treatment options (Group 2)
• People who have at least one area of cancer that can be measured on a CT or PET-CT scan, with 2 or more clearly visible spots or lymph nodes affected
• People who can provide a lymph node tissue sample (either a recent or stored sample) — this applies to Part 2 of the trial only
• People with a life expectancy of at least 12 weeks
• People whose general physical functioning falls within a certain range on a standard medical scale (rated 0, 1, or 2 out of 4, meaning they are fully active to capable of self-care but limited in physically demanding activity) (confirm with trial site)
• People whose organs (such as liver and kidneys) and blood counts are working at an adequate level at the time of screening

Who may not be able to join:

• People whose lymphoma is in, or has spread to, the brain or spinal cord
• People who have received cancer treatments — such as chemotherapy, radiation, hormone therapy, immunotherapy, or experimental drugs — within 14 days or 5 half-lives before the first study dose (whichever comes first); people who previously had CAR-T cell therapy or CD3/CD20 bispecific antibody therapy (allowed in Group 2 only) must have a gap of at least 4 weeks
• People who are currently taking part in another treatment clinical trial
• People who still have significant ongoing side effects from previous cancer treatment that have not reduced to a mild level before the first study dose
• People who have previously been treated with a type of drug called a PIM inhibitor
• People in Group 1 who have previously received any bispecific antibody therapy targeting both CD3 and CD20
• People with a known or likely allergy to the study drugs (MEN1703 or glofitamab) or their ingredients
• People who cannot take any type of medication used to lower uric acid levels
• People who have had major surgery within 1 month before the first study dose
• People who have had a stem cell transplant within 4 months before the first study dose
• People who need ongoing medication that affects the immune system, or who have a confirmed history of autoimmune disease or another condition causing long-term immune suppression
• People who have received a live or live-attenuated vaccine within 4 weeks before signing the consent form
• People with an active, uncontrolled bacterial, fungal, or viral infection (some mild infections that are improving may still be acceptable — confirm with trial site)
• People with a known HIV infection
• People with active liver disease of any kind
• People with ongoing lung inflammation caused by a drug (drug-induced pneumonitis)
• People with ongoing inflammatory bowel disease
• People with another active cancer diagnosis
• People who have recently taken certain medications that are processed through specific liver enzymes (CYP2D6) or that affect a specific drug transporter (BCRP), within 14 days or 5 half-lives before the first study dose — the trial site can advise on specific medications
• People with significant heart problems, including a heart attack in the past 6 months, severe heart failure, uncontrolled heart rhythm problems, or poorly controlled chest pain
• People who are currently being treated for an active blood clot (note: preventive treatment for a past blood clot may still be acceptable — confirm with trial site)
• People with a history of serious heart rhythm problems affecting the lower chambers of the heart, or a specific heart electrical reading (QTc) of 480 ms or more (some exceptions may apply for certain known heart conditions — confirm with trial site)
• People who have any condition that significantly affects their ability to swallow or absorb oral (by mouth) medication
• People who are planning to become pregnant or are breastfeeding during treatment and for 1 month after the last study dose
• People with any other medical condition, illness, surgical history, abnormal test results, or personal circumstances that, in the investigator's opinion, could affect safety or interfere with the trial

Important: Always verify eligibility with the trial site directly before applying.